Media headlines about Marinus Pharmaceuticals (NASDAQ:MRNS) have trended somewhat negative this week, Alpha One reports. The research group, a subsidiary of Accern, scores the sentiment of press coverage by reviewing more than 20 million news and blog sources. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Marinus Pharmaceuticals earned a news sentiment score of 0.00 on Alpha One’s scale. Alpha One also gave media headlines about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an effect on the company’s share price in the next several days.
Separately, Zacks Investment Research upgraded Marinus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a report on Friday, March 17th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Marinus Pharmaceuticals presently has an average rating of “Hold” and an average price target of $2.25.
Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) traded down 7.26% during midday trading on Friday, hitting $1.15. The company had a trading volume of 554,165 shares. Marinus Pharmaceuticals has a one year low of $0.82 and a one year high of $6.15. The company’s 50 day moving average is $1.42 and its 200 day moving average is $1.26. The firm’s market cap is $25.78 million.
Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Monday, May 1st. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.06. Equities analysts forecast that Marinus Pharmaceuticals will post ($1.00) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.themarketsdaily.com/2017/05/20/marinus-pharmaceuticals-mrns-earning-somewhat-critical-media-coverage-report-finds-updated.html.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.